The construct uses the human prostate-specific antigen promoter (referred to as PSA; proper designation KLK3) to drive transcription of the cre recombinase cDNA. The transgene was injected into fertilized FVB oocytes. Prostate-specific expression was verified by crossing to Tg(ACTB-cat,-lacZ)34Pva transgenic mice. Founder line D4 showed high, prostate-specific cre activity. (J:99524)